Pharvaris N.V.
NLValuation Metrics
Pharvaris N.V.'s Market Cap is $2.34B. At end of 2025 it was $935M. Ranked #1871 of 3,116 in US market (top 60%), #686 of 1,472 on NASDAQ (top 47%), #117 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 44%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.34B | US#1,871/3,116 Sec#117/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-194M | US—/3,116 Sec—/265 |
| Total Assets | $386M | US#2,848/3,116 Sec#190/265 |
| Net Assets | $353M | US#2,435/3,116 Sec#146/265 |
| Employees | 134 | US#2,561/3,116 Sec#155/265 |
| Value | ||
| P/B | 6.63x | US#2,398/3,116 Sec#166/265 |
| FCF Yield | -7.53% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -54.85% | US#2,691/3,116 Sec#164/265 |
| ROA | -50.20% | US#2,983/3,116 Sec#214/265 |
| Financial Health | ||
| Debt Ratio | 9.26% | US#98/3,116 Sec#46/265 |
| Total Debt | $791448.00 | US#2,973/3,116 Sec#243/265 |
| FCF | $-176M | US#2,756/3,116 Sec#199/265 |
| Cash | $374M | US#1,249/3,116 Sec#70/265 |
| Current Ratio | 11.94x | US#202/3,116 Sec#63/265 |
| Performance | ||
| 1Y Return | 50.81% | US#477/3,116 Sec#70/265 |
| 1M Return | 7.44% | US#1,176/3,116 Sec#76/265 |
| From 52W High | -22.52% | US#1,652/3,116 Sec#97/265 |
| 1Y MDD | -28.62% | US#1,206/3,116 Sec#60/265 |
| Trading | ||
| Volume | 551,188 shares | US#1,611/3,116 Sec#163/265 |
| Trading Value | $18M | US#1,675/3,116 Sec#124/265 |
| Per Share | ||
| EPS | $-2.77 | US—/3,116 Sec—/265 |
| BPS | $5.06 | US#2,266/3,116 Sec#126/265 |
Company Info
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.